Estimating the potential public health and economic impact of vaccination strategies with an adapted vaccine in Colombia using a combined Markov-decision tree model
Jair Alberto Arciniegas,
No information about this author
Juan Manuel Reyes,
No information about this author
Carlos Fernando Mendoza
No information about this author
et al.
Expert Review of Vaccines,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 26, 2025
Background
Using
adapted
COVID-19
vaccines
targeting
current
variants
in
circulation
is
necessary
for
addressing
the
dynamic
evolution
of
SARS-CoV-2
virus
and
protecting
against
emerging
variants.
This
study
evaluated
impact
various
vaccination
strategies
with
an
vaccine
Colombia.
Language: Английский
A Response to: A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework’
Infectious Diseases and Therapy,
Journal Year:
2024,
Volume and Issue:
13(10), P. 2195 - 2202
Published: Aug. 24, 2024
Language: Английский
A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-analysis Using the GRADE Framework’
Infectious Diseases and Therapy,
Journal Year:
2024,
Volume and Issue:
13(10), P. 2203 - 2206
Published: Aug. 24, 2024
incorrect
estimates
that
not
only
greatly
exaggerated
the
numerical
differences
in
VE
between
two
vaccines
but
also
led
to
conclusions
directly
contradicted
those
of
original
study
authors
many
instances.As
a
brief
example
this
(see
Supplementary
Appendix
for
additional
details),
wherein
one
studies
concluded
"there
was
no
difference
BNT162b2
versus
mRNA-1273
recipients
[3]"
based
on
their
reported
adjusted
results,
Kavikondala
et
al.
instead
calculated
and
used
63%
crude
relative
as
point
estimate
meta-analysis.This
mistake-where
found
these
vaccines,
yet
random
effects
risk
ratios
by
significantly
favored
mRNA-1273-occurred
20/54
(37%)
all
(from
24
included
studies)
Fig.
3a-e.In
addition,
there
were
eligible
missed
systematic
review
(i.e.,
at
least
14
extensive
errors
data
extraction.These
concerns
are
described
detail
Appendix.Second,
set
out
compare
BNT162b2,
so
they
should
have
head-to-head
estimates.Comparative
better
account
potential
brand-specific
population
characteristics
vaccine
(e.g.,
age
or
COVID-19
status)
timing
Language: Английский
Comment on Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(10), P. 1174 - 1174
Published: Oct. 17, 2024
We
noted
three
key
inconsistencies
in
the
Moderna-funded
cost-effectiveness
analysis
by
Fust
et
al
[...].
Language: Английский
Reply to Volkman et al. Comment on “Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434”
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(10), P. 1175 - 1175
Published: Oct. 17, 2024
In
their
comment
[...].
Language: Английский